Under the collaboration, the organisations intend to initially develop and manufacture vaccines for flu, dengue fever and West Nile virus.
Phillip Frost, chairman and CEO of Opko, said: “This initial step to develop a long and productive relationship with CIATEJ follows our purchase of Pharmacos Exacta, with offices and manufacturing facilities in Guadalajara, Mexico.
“The acquisition of Exakta and our collaboration with CIATEJ furthers our strategy of expanding commercial activities while we continue to develop important therapeutic and diagnostic products.”